Modafinil (Provigil) Complete Drug-Drug Interaction Profile

How Modafinil Works: The Pharmacology Behind Its Interactions

Modafinil promotes wakefulness through a mechanism distinct from traditional amphetamine-type stimulants. The drug increases extracellular dopamine by binding the dopamine transporter (DAT) and blocking reuptake, as demonstrated by Volkow et al. in a PET imaging study of 10 healthy males given 200 mg or 400 mg doses 1. It does not trigger the broad catecholamine surge seen with amphetamines.

Beyond dopamine, modafinil activates hypothalamic orexin/hypocretin neurons and raises histamine release in the tuberomammillary nucleus 2. These pathways explain its targeted wake-promoting effect without the cardiovascular overstimulation common to older psychostimulants. The US Modafinil in Narcolepsy Study Group confirmed clinical efficacy in 1998, showing significant reductions in Epworth Sleepiness Scale scores across 283 narcolepsy patients without amphetamine-class adverse effects 3.

Why does pharmacology matter for interactions? Modafinil's real interaction risk comes not from its receptor targets but from its behavior in the liver. It acts as a moderate inducer of CYP3A4/5 and a reversible inhibitor of CYP2C19 4. This dual enzyme profile creates two opposite clinical problems: it can speed up the clearance of some drugs while slowing the metabolism of others.

CYP3A4 Induction: Which Drugs Lose Efficacy

Modafinil's induction of CYP3A4 is the interaction most likely to cause clinical harm. CYP3A4 metabolizes roughly 50% of all marketed drugs, so the list of potentially affected medications is large.

The FDA-approved Provigil label specifically warns about reduced efficacy of the following drug classes when co-administered with modafinil 5:

Hormonal contraceptives. Steroidal contraceptives (pills, patches, rings, implants) rely on CYP3A4 for activation and clearance balance. Modafinil accelerates the clearance of ethinyl estradiol and norgestimate. The FDA label states that alternative or additional contraception is required during modafinil therapy and for one month after discontinuation. A pharmacokinetic study showed a 10 to 20% decrease in ethinyl estradiol AUC at steady-state modafinil dosing 5. That magnitude is enough to push some patients below the threshold for ovulation suppression.

Cyclosporine. A published case report documented a 50% reduction in cyclosporine blood concentrations in a transplant patient after modafinil was added 6. Organ rejection becomes a real risk. Transplant teams should monitor trough levels weekly for at least four weeks after modafinil initiation.

HIV protease inhibitors. Indinavir, ritonavir, saquinavir, and other PI-based regimens undergo extensive CYP3A4 metabolism. Reduced PI levels can cause viral breakthrough and resistance development 5. The Provigil label lists this as a specific precaution.

Calcium channel blockers and statins. Amlodipine, felodipine, simvastatin, and atorvastatin are CYP3A4 substrates. Clinicians prescribing these alongside modafinil should watch for loss of blood pressure control or rising LDL values.

CYP2C19 Inhibition: Which Drug Levels Rise

The opposite problem. Modafinil inhibits CYP2C19, which means substrates of this enzyme accumulate to higher plasma concentrations than expected.

Diazepam clearance dropped by approximately 37% when co-administered with modafinil in a controlled pharmacokinetic study referenced in the FDA label 5. For a drug with a half-life already exceeding 40 hours in some patients, this creates prolonged sedation risk. The irony is striking: a wakefulness agent can amplify the effects of a sedative.

Omeprazole and other proton pump inhibitors. Omeprazole is a CYP2C19 substrate. Modafinil co-administration can increase omeprazole exposure by roughly 40% in extensive metabolizers 4. For most patients this creates no symptoms. For CYP2C19 poor metabolizers (2 to 5% of Caucasians, up to 20% of East Asian populations), the compounding effect may raise omeprazole levels enough to increase magnesium depletion risk with long-term use 7.

Phenytoin. Phenytoin has a narrow therapeutic index and is partially cleared by CYP2C19. Adding modafinil can push phenytoin into the toxic range. The Provigil label recommends monitoring phenytoin plasma levels during the first two months of co-administration and after dose changes to either drug 5.

Clopidogrel (reverse concern). Clopidogrel is a prodrug activated by CYP2C19. Inhibiting this enzyme with modafinil could theoretically reduce clopidogrel's antiplatelet effect. No published clinical study has quantified this interaction, but the pharmacokinetic logic warrants caution in post-stent patients 8.

Warfarin: A Two-Pathway Problem

Warfarin demands its own section. The S-enantiomer (the more potent anticoagulant form) is metabolized by CYP2C9, while the R-enantiomer is cleared partly through CYP1A2 and CYP3A4 9. Modafinil's weak induction of CYP1A2 and moderate induction of CYP3A4 could reduce R-warfarin exposure, while its effects on CYP2C19 introduce an indirect variable through altered competition among CYP2C-family enzymes.

The net clinical effect is unpredictable. Some patients will see INR drift downward. Others may not change at all. The FDA label requires more frequent INR monitoring when modafinil is started, stopped, or dose-adjusted in patients taking warfarin 5. Check INR at least weekly for the first month, then biweekly for another month.

The CYP2C19 Polymorphism Layer

Genetic variation in CYP2C19 adds complexity to every modafinil interaction involving this enzyme. Approximately 2 to 5% of European-descent populations and 13 to 23% of East Asian populations carry two loss-of-function alleles (*2/*2 or *2/*3), making them poor metabolizers 10.

In poor metabolizers, CYP2C19 contributes almost nothing to drug clearance at baseline. Adding modafinil's inhibitory effect on an already non-functional enzyme has minimal incremental impact. The clinical concern is the opposite phenotype: ultra-rapid metabolizers (CYP2C19 *17/*17, found in roughly 5 to 30% of various populations) who depend heavily on CYP2C19 activity. For these patients, modafinil's inhibition causes a proportionally larger swing in substrate drug levels 10.

Pharmacogenomic testing is not required before prescribing modafinil. But when a patient on modafinil shows unexpectedly high or low levels of a CYP2C19 substrate, genotyping provides an explanation.

Interactions with Psychotropic Co-Medications

Patients prescribed modafinil frequently take other CNS-active drugs. The interaction profile in this class is nuanced.

SSRIs and SNRIs. Fluoxetine and fluvoxamine are CYP2C19 inhibitors themselves. Adding modafinil creates additive CYP2C19 inhibition, potentially raising levels of any third drug metabolized by this pathway. Sertraline, which is partially a CYP2C19 substrate, may see modest increases in plasma levels during modafinil co-administration 11. Dose adjustment is rarely needed, but prescribers should monitor for serotonergic side effects.

Clomipramine and tricyclics. The Provigil label specifically mentions clomipramine and desipramine. In a patient with a CYP2D6 deficiency, where CYP2C19 becomes the backup clearance pathway, modafinil-mediated inhibition of CYP2C19 could cause tricyclic levels to rise into the cardiotoxic range 5. ECG monitoring is appropriate for any tricyclic combined with modafinil.

Methylphenidate. Methylphenidate is sometimes combined with modafinil in treatment-resistant hypersomnia. A pharmacokinetic study in 32 subjects found that co-administration delayed methylphenidate absorption by approximately one hour but did not change overall exposure (AUC) 5. The clinical significance is minimal.

MAO inhibitors. No published pharmacokinetic data exist for the modafinil-MAOI combination. The Provigil label does not contraindicate it. Caution is still advised given modafinil's dopaminergic activity.

Alcohol and Recreational Substances

Modafinil does not appear to alter ethanol pharmacokinetics, but the combination creates a cognitive mismatch. A study by Marczinski and Fillmore found that modafinil reduced subjective feelings of intoxication without improving actual psychomotor impairment in 11 healthy volunteers given alcohol 12. Patients may drink more because they feel less drunk. Clinicians should counsel patients about this masking effect directly.

Cannabis compounds (THC, CBD) undergo CYP3A4 metabolism. Modafinil's induction of this enzyme could reduce cannabinoid plasma levels, though no formal interaction study exists.

Food and Timing Interactions

Food delays modafinil absorption by approximately one hour but does not reduce total bioavailability 5. Grapefruit juice, a well-known CYP3A4 inhibitor, could theoretically blunt modafinil's own induction effect, but no clinical data support dose adjustment based on grapefruit intake.

The timing of modafinil dosing relative to CYP3A4 substrates matters. Peak enzyme induction occurs at steady state, typically after seven days of daily dosing. When modafinil is stopped, CYP3A4 activity returns to baseline over approximately two to three weeks. Drugs that were under-dosed due to induction (contraceptives, cyclosporine) may temporarily overshoot during this washout period.

Practical Prescriber Decision Framework

Prescribers adding modafinil to an existing medication regimen should follow a structured review:

1. List all CYP3A4 substrates. Check whether any are narrow-therapeutic-index drugs (cyclosporine, tacrolimus, sirolimus) or medications where efficacy loss causes serious harm (contraceptives, antiretrovirals). Adjust monitoring or switch to non-interacting alternatives.

2. List all CYP2C19 substrates. Flag phenytoin, diazepam, clopidogrel, voriconazole, and proton pump inhibitors. Reduce doses or increase monitoring frequency.

3. Check warfarin status. If the patient takes warfarin, increase INR monitoring to weekly for four weeks after any modafinil dose change.

4. Evaluate contraceptive method. Recommend copper IUD or depot medroxyprogesterone acetate (DMPA, which relies on progestational effect independent of hepatic clearance) as alternatives to combined oral contraceptives.

5. Review CYP2C19 genotype if available. Ultra-rapid metabolizers face greater interaction magnitude for CYP2C19 substrates.

6. Reassess at discontinuation. Remind patients that enzyme induction effects persist for two to four weeks after stopping modafinil. Contraceptive alternatives should continue for one full month post-discontinuation per the FDA label 5.

Armodafinil: Same Interactions, Different Kinetics

Armodafinil (Nuvigil) is the R-enantiomer of modafinil. It shares the same CYP3A4 induction and CYP2C19 inhibition profile 13. The key pharmacokinetic difference is a longer effective half-life producing higher late-day plasma concentrations at equivalent doses. All interaction precautions that apply to modafinil apply identically to armodafinil. Do not assume switching enantiomers eliminates interaction risk.

Prescribers managing a patient on 200 mg modafinil who switch to armodafinil 150 mg (the labeled equivalent) should re-check interacting drug levels, because the sustained higher afternoon concentrations of armodafinil may produce a slightly different induction profile in the CYP3A4 system across a 24-hour period.

The Endocrine Society's 2017 clinical practice guideline on pharmacogenomics notes that enzyme inducers with half-lives exceeding 12 hours require at least one full elimination cycle of the affected substrate drug before interaction magnitude can be assessed 14. For modafinil, with its 12 to 15 hour half-life, steady-state induction is reached by day seven.